The equine herpesvirus 1 glycoprotein 14 (EHV-1 gpl4) gene was cloned, sequenced, and expressed by vaccinia virus recombinants. Recombinant virus vP613 elicited the production of EHV-1-neutralizing antibodies in guinea pigs and was effective in protecting hamsters from subsequent lethal EHV-1 challenge. Coexpression of EHV-1 gpl4 in vaccinia virus recombinant vP634 along with EHV-1 gpl3 (P. Guo, S. Goebel, S. Davis, M. E. Perkus, B. Languet, P. Desmettre, G. Allen, and E. Paoletti, J. Virol. 63:41894198, 1989) greatly enhanced the protective efficacy in the hamster challenge model over that obtained with single recombinants. The inoculum doses (loglo) required for protection of 50% of hamsters were 6.1 (EHV-1 gpl3), 5.2 (EHV-1 gpl4), and <3.6 (vaccinia virus recombinant expressing both EHV-1 glycoproteins [gpl3 and gpl4]).
gpl4]).
There are two subtypes of equine herpesvirus that, although cross-neutralizable, can be distinguished by their antigenic profiles, restriction endonuclease profiles, and pathogenicity for horses (3) . Equine herpesvirus 1 (EHV-1) is associated with respiratory tract disease, central nervous system disorders, and classic herpetic abortions, whereas equine herpesvirus 4 (EHV-4) is predominantly associated with respiratory tract disease (3, 28) . Equine herpesviruses are members of the alphaherpesvirus subfamily and display many of the typical biological and biochemical characteristics of human herpesviruses, such as genomic isomerization, regulation of gene expression, establishment of latent infections, generation of defective interfering virus particles, induction of neurological disorders, and in vitro oncogenic transformation (3, 5, 29) . Thus, equine herpesviruses represent a useful system for studying the varied biological consequences of herpesvirus infections.
Herpesvirus glycoproteins mediate essential viral functions, such as cellular attachment and penetration and cellto-cell spread of the virus, and, importantly, determine the pathogenicity profile of infection. Herpesvirus glycoproteins are critical components in the interaction with the host immune system (45, 46) . Both subtypes of equine herpesvirus express six abundant glycoproteins (3, 4, 53) . The genomic portions of the EHV-1 DNA sequences encoding glycoprotein 2 (gp2), gplO, gpl3, gpl4, gpl7/18, and gp2l/22a have been determined with lambda gtll expression vectors and monoclonal antibodies (4) . gpl3 and gpl4 were located in the same locations within the L component of the genome to which the gC and gB homologs, respectively, of herpes simplex virus map (4) . Recently, the nucleotide sequence of the Kentucky T431 strain of the EHV-1 transcriptional unit encoding gpl3 was reported (2, 18) shown to be homologous to herpes simplex virus gC-1 and gC-2, to pseudorabies virus glll, and to varicella-zoster virus gpV (2, 18) . EHV-1 gpl3 is thus the structural homolog of the herpesvirus gC glycoproteins.
EHV-1 gpl3 was expressed in vaccinia virus (18 
965 3351 the 18S rRNA sequence 3'-AGGAAGGCGT-5' (19) and may serve as the ribosome-binding site. Analysis of the amino acid sequence revealed a number of features common to membrane-associated glycoproteins. A region extending from amino acids 58 to 99 had a characteristic hydrophobicity profile and is proposed to be the signal sequence. An unusual feature of the EHV-1 gpl4 gene is that the long hydrophobic signal sequence is preceded by a long hydrophilic sequence. This characteristic has also been noted for the pseudorabies virus gII (39) and bovine herpesvirus 1 gI (58) genes. A hydrophobic region consisting of 45 amino acids (amino acids 826 to 870) is predicted to function as a transmembrane anchor domain. The hydrophilic cytoplasmic domain contains 110 amino acids. There are 13 Asn-X-Thr/Ser (where X can be any amino acid except proline) sites for potential N-linked glycosylation (27) . An unusual feature is that there are two potential glycosylation sites in the cytoplasmic domain (Fig. 1) . A comparison of the amino acid compositions of the EHV-1 gpl4 gene and other herpesvirus glycoprotein genes revealed extensive homology. Thus, EHV-1 gpl4 is homologous to gII of pseudorabies virus (39) , gI of bovine herpesvirus 1 (58), gIl of varicella-zoster virus (14) , gB of herpes simplex virus (9), glycoprotein BALF-4 of Epstein-Barr virus (32) , and gB of human cytomegalovirus (12) . These results are in good agreement with recent reports on the sequence analysis of gpl4 of EHV-4 (38) and gpl4 of isolate HVS-25A of EHV-1 (57) . In a comparison of the amino acid sequence of EHV-1 gpl4 reported here with that of EHV-4 gpl4 (38), 83% overall identity was found. However, in a comparison ofjust the amino acids comprising the predicted mature protein, the homology was 93%. As would be expected, the derived amino acid sequence of EHV-1 gpl4 reported here was even more similar to that reported for EHV-1 isolate HVS-25A gpl4 (57) . The DNA sequence was identical except for one short region. We found a second G at position 1074 and one less G at position 1102. The amino acids encoded between these two positions are V, P, S, K, F, A, T, P, and G instead of C, R, P, S, L, Q, L, R, and G. Significantly, the deduced amino acid sequence reported here over this region of EHV-1 was identical to the corresponding sequence reported for EHV-4 (38) .
Lambda gtll expression vectors and monoclonal antibodies have been useful in identifying the EHV-1 DNA sequences encoding the major EHV-1 glycoproteins (4). A lambda gtll recombinant, 4al, was shown to express an EHV-1 gpl4 epitope recognized by the specific monoclonal antibody 3F6 (4). For determination of the identity of this epitope, the EHV-1 DNA contained within 4al was sequenced and compared with the DNA of the EHV-1 gpl4 coding sequence (Fig. 1) . The nucleotide sequence alignment indicated that this epitope was contained within the 66-amino-acid region corresponding to amino acids 107 (Thr) through 172 (Val) of the deduced primary translation product. The epitope is therefore located within the aminoterminal region of the deduced EHV-1 gpl4 surface domain. (41) , this gene, which is located immediately to the right of MlL (52), was designated M2L. Figure 2 details the construction of recombinant vaccinia virus vP458, in which the M2L gene is replaced by the E. coli lacZ gene under the control of the vaccinia virus 11-kDa promoter (8) .
The gene for EHV-1 gpl4 was cloned into the M2L deletion locus under the control of the vaccinia virus H6 promoter (18, 33) . Several recombinants containing different amounts of the unusually long EHV-1 gp14 leader sequence were constructed. Vaccinia virus recombinant vP613 contains a truncated version of gp14 in which amino acids 2 to 34 are replaced by 4 amino acids derived from synthetic linkers (Fig. 3) .
To obtain vaccinia virus recombinants containing both EHV-1 gpl4 and EHV-1 gp13, we performed in vivo recombination with vP613 as the rescuing virus and donor plasmid pVHA6gl3 (18) . pVHA6g13 contains the EHV-1 gpl3 gene under the control of the H6 promoter inserted at the vaccinia virus HA deletion locus. Recombination of pVHA6g13 with vaccinia virus recombinant vP613 generated the vaccinia virus recombinant vP634 containing both EHV-1 gp13 and EHV-1 gp14.
Confirmation of the presence of both EHV-1 genes was obtained by in situ hybridization of 32P-labeled probes specific for either EHV-1 gp13 or EHV-1 gp14. Expression of the respective EHV-1 antigens was assessed by immunoprecipitation of metabolically radiolabeled polypeptides specifically reactive with monoclonal antibody 14H7 (gpl3) of the vaccinia virus HindIlI M fragment with the location of the M2L gene and relevant restriction sites indicated. The vaccinia virus HindIlI M fragment was cloned into pUC8 cut with HindIII, resulting in plasmid pSD409VC. For removal of unwanted vaccinia virus DNA and restriction sites, the right vaccinia virus arm was shortened by digestion of pSD409VC with BamHI-BglII and ligated, resulting in pMP409BVC. For removal of the M2L gene, pMP409BVC was digested with SphI, followed by limited digestion with BAL-31 exonuclease and mutagenesis (23) with a synthetic 49-mer oligonucleotide (5'-TTTCTGTATATTTGCAACAATTTAGATETACTCAAAATATGTAA CAAT-3'; the BglII site is underlined). In the mutagenized plasmid, pMP409DVC, the M2L coding sequence was deleted from position +3 through the end of the open reading frame. The G of the initiation codon was changed to a C to create a unique BglII site (AGAT(CT) at the deletion junction. A BglII-BamHI cassette containing the E. coli ,-galactosidase gene (44) under the control of the vaccinia virus 11-kDa promoter (8) was inserted into pMP409DVC cut with BglII, resulting in plasmid pMP409DVCBG. pMP409DVCBG was used as a donor plasmid for in vivo recombination with the rescuing virus vP410 (18) . The resulting vaccinia virus recombinant, vP458, contains the E. coli ,-galactosidase gene under the control of the 11-kDa vaccinia virus promoter inserted into the M2L deletion locus in a right-to-left orientation relative to flanking vaccinia virus sequences. Vaccinia virus recombinant vP458 was detected by ,-galactosidase gene expression with the chromogenic 5-bromo-4-chloro-3-indolyl-3-D-galactopyranoside substrate (11, 30) (20) with uracil-containing plasmid DNA produced in the dut, ung host E. coli CJ236. In the mutagenized plasmid, an NsiI site was created at codons 1 and 2 of the EHV-1 gpl4 gene, changing the sequence ATG/TCC (Met/Ser) to ATG/CAT (Met/His). The KpnI-BamHI fragment from the mutated plasmid was transferred to KpnI-BamHI-digested pUC18. (B) Cloning of the 3' end of the gene. The 7.1-kilobase EHV-1 BamHI i fragment containing the 3' end of the EHV-1 gp14 gene was cloned into pUC8 cut with BamHI. Extraneous DNA was removed by digestion of the plasmid with PstI, followed by self-ligation, resulting in plasmid pUC (BamHI-PstI). For assembly of the entire EHV-1 gpl4 gene in one plasmid, a BamHI-EcoRI fragment from panel A containing the mutated 5' end of the EHV-1 gpl4 gene was ligated into pUC (BamHI-PstI) cut with BamHI-EcoRI, resulting in plasmid pUCgl4. (C) Insertion of the EHV-1 gpl4 gene into vaccinia virus flanking arms. The synthetic H6 promoter (33) containing an NsiI site at the ATG initiation codon was inserted into the Copenhagen M2L deletion vector plasmid pMP409DVC, generating plasmid pMG11. An NsiI-EcoRI fragment containing the promoter and right vaccinia virus flanking arm was isolated from pMG11 and ligated into pUCgl4 cut with Nsil-EcoRI. An HpaI-PstI fragment containing the right vaccinia virus arm and the EHV-1 gpl4 gene under the control of the H6 promoter was ligated into the pMG11 vector plasmid cut with HpaI-PstI. The resulting plasmid, pVM2LH6gl4, contained the H6 promoter-EHV-i gpl4 gene flanked by vaccinia virus arms. (D) Truncation of the EHV-1 gpl4 gene and generation of vaccinia virus recombinant vP613. An NsiI site was added to the Bluescript SK+-based clone containing the 5' end of the EHV-1 gpl4 gene at codons 32 to 34 by mutagenesis as described for panel A. An Nsil-BamHI fragment containing the 5' end of the gp14 gene in pVM2LH6gl4 was replaced with an NsiI-BamHI fragment containing the newly mutagenized truncated 5' end of the gene. Synthetic NsiI linkers were added to bring the ATG initiation codon in-frame with the gene. In the resulting plasmid, pVM2LH6gl4-1, the sequence of the truncated 5' end of EHV-1 gpl4 is ATG/CAT/GCA/TGC/ATT/GCT, encoding Met/His/Ala/Cys/Ile/Ala, where GCT (Ala) is codon 35 of EHV-1 gpl4. In vivo recombination was performed with donor plasmid pVM2LH6gl4-1 and rescuing virus vP458, generating vaccinia virus recombinant vP613.
Sullivan et al. (47) , corresponding to the full-length glycosylated gpl4 gene product and its cleavage products (76 and 58 kDa). The EHV-1 gpl4 amino acid sequence (Fig. 1) contains the Arg/Arg/Ser tripeptide sequence at amino acids 520 through 522 which has been proposed to specify cleavage after Arg (amino acid 521) of the EHV-1 gpl4 gene product (57) . Glycosylation of the primary gpl4 translation product, accompanied by cleavage after amino acid 521, would generate the 57-and 72-to 82-kDa polypeptides observed. These polypeptides are known to be disulfide linked (26, 47) and thus coprecipitated by monoclonal antibody 3F6 in the absence of reducing reagents. Further, both EHV-1 antigens were localized on the membrane of vP634-infected cells, as detected by immunofluorescence (data not shown). (7, 10, 13, 21, 24, 25, 31, 35, 40, 55, 59, 60) . gC can stimulate class I-restricted cytotoxic lymphocytes (17, 42) , whereas gD can stimulate class II cytotoxic T-cell responses (24, 25, 55, 59, 60) . gG has been shown to be a target for complement-dependent antibody-directed virus neutralization (48, 49) . A number of glycoproteins from other herpesviruses have also been shown to elicit important immune responses (6, 12, 18, 45, 54) .
In 
